退伍军人事务部糖尿病试验(VADT)中强化血糖控制对肾脏结局的长期随访
VADT将1791例2型糖尿病退伍军人随机分配至强化或标准血糖控制,中位干预5.6年,后续VADT-F随访至2013年12月,1033例同意参与。强化组维持eGFR>60 ml min-1 1.73 m-2的比值比(OR)为1.34(95%CI 1.05,1.71,p=0.02),KDIGO风险类别改善的RR为6.1(p=0.002)。
要点
- VADT强化血糖控制中位5.6年,随访超过11年后强化组维持eGFR>60的OR为1.34(95%CI 1.05,1.71,p=0.02)。
- 基线KDIGO中危者强化vs标准RR为1.3(p=0.03),高危者RR为2.3(p=0.04)。
- VADT-F结束时强化组改善至低KDIGO风险类别的RR为6.1(p=0.002)。
核心结论
- 随访超过11年后,接受中位5.6年强化血糖控制的2型糖尿病患者维持eGFR>60 ml min-1 1.73 m-2的比值增加34%,KDIGO类别改善的比值也更高。
研究设计与样本
- VADT将来自20个退伍军人事务医疗中心的1791例2型糖尿病退伍军人随机分配至强化或标准血糖控制,中位干预5.6年(随机化2000年12月至2003年5月,干预于2008年5月结束)。
- 试验结束后参与者通过退伍军人事务系统内自身医生接受常规照护;本次为VADT-F(2008年6月至2013年12月)的中期分析。
- 使用退伍军人事务部和国家数据库收集数据,报告1033例签署知情同意参与VADT-F者的基于血清肌酐、eGFR和尿白蛋白与肌酐比值(ACR)的肾脏结局。
主要发现
- VADT-F结束时,VADT期间接受强化治疗者维持eGFR>60 ml min-1 1.73 m-2的OR为1.34(95%CI 1.05,1.71,p=0.02)。
- 基线按KDIGO慢性肾脏病分类为中危者强化vs标准RR为1.3(p=0.03),高危者RR为2.3(p=0.04)。
- VADT-F结束时强化组改善至低KDIGO风险类别的RR为6.1(p=0.002)。
- VADT-F期间强化与标准组平均HbA1c、血压或血脂水平无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: We conducted an analysis of data collected during the Veterans Affairs Diabetes Trial (VADT) and the follow-up study (VADT-F) to determine whether intensive (INT) compared with standard (STD) glycaemic control during the VADT resulted in better long-term kidney outcomes. METHODS: VADT randomly assigned 1791 veterans from 20 Veterans Affairs (VA) medical centres who had type 2 diabetes mellitus and a mean HbA1c of 9.4 ± 2% (79.2 mmol/mol) at baseline to receive either INT or STD glucose control for a median of 5.6 years (randomisation December 2000 to May 2003; intervention ending in May 2008). After the trial, participants received routine care through their own physicians within the VA. This is an interim analysis of the VADT-F (June 2008 to December 2013). We collected data using VA and National databases and report renal outcomes based on serum creatinine, eGFR and urine albumin to creatinine ratio (ACR) in 1033 people who provided informed consent to participate in the VADT-F. RESULTS: By the end of the VADT-F, significantly more people who received INT treatment during the VADT maintained an eGFR >60 ml min-1 1.73 m-2 (OR 1.34 [95% CI 1.05, 1.71], p = 0.02). This benefit was most evident in those who were classified as at moderate risk (INT vs STD, RR 1.3, p = 0.03) or high risk (RR 2.3, p = 0.04) of chronic kidney disease on the Kidney Disease Improving Global Outcomes (KDIGO-CKD) at the beginning of VADT. At the end of VADT-F, significantly more people from the INT group improved to a low KDIGO risk category (RR 6.1, p = 0.002). During the VADT-F there were no significant differences between INT and STD for average HbA1c, blood pressure or lipid levels. CONCLUSIONS/INTERPRETATION: After just over 11 years of follow-up, there was a 34% greater odds of maintaining an eGFR of >60 ml min-1 1.73 m-2 and of improving the KDIGO category in individuals with type 2 diabetes who had received INT for a median of 5.6 years. VADT clinical trials.gov number: NCT 00032487.
引用
- Agrawal L, Azad N, Bahn GD, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2017. PMID: 29101421. doi:10.1007/s00125-017-4473-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。